玻璃体腔注射贝伐单抗（阿瓦斯汀）治疗早产儿 1 型糖尿病视网膜病变。
Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
机构信息
Department of Ophthalmology, Hospital de Niños Roberto del Rio, Santiago, Chile.
出版信息
Retina. 2010 Apr;30(4 Suppl):S24-31. doi: 10.1097/IAE.0b013e3181ca1457.
PURPOSE
The purpose of this study was to report a noncomparative consecutive case series of eyes with type 1 retinopathy of prematurity treated only with intravitreal bevacizumab (Avastin).
METHODS
Twelve consecutive eyes of 7 premature infants, with type 1 retinopathy of prematurity as stated in the Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial, were treated with only one intravitreal injection of bevacizumab (0.625 mg). RetCam pictures were used to document the cases.
RESULTS
Nine eyes had zone I and 3 eyes had zone II retinopathy of prematurity. The infants weighed between 600 and 1,100 grams (mean, 846.57 g). The gestational age ranged from 23 weeks to 28 weeks (mean, 25.57 weeks). All eyes showed regression of the disease with no additional treatment needed.
CONCLUSION
Intravitreal bevacizumab is a useful therapy for type 1 retinopathy of prematurity. However, additional studies are needed to define the role of Avastin as the first-line therapy, in combination, or after the failure of laser photocoagulation.
目的
本研究旨在报告仅接受玻璃体腔内注射贝伐单抗（阿瓦斯汀）治疗的 1 型早产儿视网膜病变的非对照连续病例系列。
方法
7 名早产儿的 12 只连续眼，符合早产儿视网膜病变早期治疗随机试验的结果中所述的 1 型早产儿视网膜病变，仅接受单次玻璃体腔内注射贝伐单抗（0.625mg）治疗。使用 RetCam 图片记录病例。
结果
9 只眼有 1 区病变，3 只眼有 2 区病变。婴儿体重在 600 至 1100 克之间（平均 846.57 克）。胎龄从 23 周到 28 周不等（平均 25.57 周）。所有眼睛的疾病均有消退，无需进一步治疗。
结论
玻璃体腔内注射贝伐单抗是治疗 1 型早产儿视网膜病变的有效方法。然而，还需要更多的研究来确定阿瓦斯汀作为一线治疗、联合治疗或激光光凝失败后的治疗选择的作用。
Zotero 插件